Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
AdAlta licenses Alzheimer's disease-specific shark antibodies... | CPHI ...
AdAlta at a glance - AdAlta - next generation cell and protein therapeutics
AdAlta and GPCR link up with claim of new cancer treatment approach ...
Home - AdAlta - Developing i-body drugs to treat fibrotic diseases
Preference Test - AdAlta - next generation cell and protein therapeutics
AdAlta Ltd's June 2025 Quarterly Report highlights tailwinds behind our ...
AdAlta investor briefing – progress of AD-214 Phase I extension study ...
AdAlta to support early return to clinical trials of AD-214 with rights ...
AdAlta completes enrolment for AD-214 fibrosis safety trial - YouTube
AdAlta (ASX:1AD) showcased its clinical stage pipeline oppoertunities ...
AdAlta's i-body platform: reaching for the high-hanging fruit - AdAlta ...
AdAlta (ASX:1AD) has announced significant progress in Q4 FY24. Key ...
AdAlta licenses Alzheimer’s disease-specific shark antibodies to ...
AD-214: A new approach to fibrotic disease - AdAlta - next generation ...
ADALTA EDUCATION SERIES, Issue One: Fibrosis - AdAlta - next generation ...
Home - AdAlta - next generation cell and protein therapeutics
AdAlta advanced both its East to West cellular immunotherapy strategy ...
AdAlta completes enrolment for AD-214 fibrosis safety trial | ASX:1AD
AdAlta (ASX:1AD) targeting idiopathic pulmonary fibrosis - Sequoia Direct
ASX Health Stocks: AdAlta jumps 40pc after its fibrosis drug shows ...
AdAlta proudly continues its series of posts on the specialists making ...
AdAlta links AD-214 results with efficacy thanks to new data - YouTube
Adalta Real - Bicester Vision
Break it Down: AdAlta moves into a higher realm of drug development ...
AdAlta completes patient recruitment for AD-214 study to treat ...
AdAlta presents at Investor Summit - AdAlta - next generation cell and ...
AdAlta secures Cell Therapies as cellular immunotherapies manufacturer ...
AdAlta named as Finalist in Australian Technologies Competition ...
topical - AdAlta - next generation cell and protein therapeutics
StockTake: AdAlta eyes $1.3m boost to fuel East to West cellular ...
Bioshares: AdAlta prioritises IV formulation for AD-214 - AdAlta - next ...
AdAlta Limited: Fibrosis briefing highlights February 2017 - YouTube
AdAlta Rights Offer webinar recording, Wednesday 3 May 2023 - AdAlta ...
#1ad | AdAlta Ltd
AdAlta secures $1.9m from exercise of options to advance critical ...
Our October Highlights have landed for Adalta Global Inc.! What a month ...
AdAlta locks in $3.7m to speed up Phase II clinical trials, near-term ...
AdAlta welcomes long-term support from Yuuwa Capital investors - YouTube
#fibrosis #ipf #biotech | AdAlta Ltd
Adalta logo - APR.Intern
AdAlta (ASX:1AD), in partnership with La Trobe University, AdAlta has ...
AdAlta (ASX:1AD) launches $1.2M placement to advance AD-214 clinical ...
AdAlta partners with SYNthesis for immunotherapy launch | AdAlta Ltd ...
Adalta Costa Rica 2025 Company Profile: Valuation, Funding & Investors ...
i-bodies - AdAlta - next generation cell and protein therapeutics
AdAlta prioritises ‘East to West’ cellular immunotherapy strategy to ...
LIMS-embedded biotech, AdAlta Limited, has been awarded $1M from the ...
AdAlta (1AD): SYNThesis BioVentures MoU for Cellular Immunotherapies ...
AdAlta delivers positive Phase I Extension Study results for AD-214 ...
Kingdom of Adalta | The Mahrym Saga
AdAlta (Discovery Tools) 2026 Company Profile: Stock Performance ...
AdAlta gets commercial-ready after pre-clinical safety studies show ...
Working at Adalta Recruitment Solutions | Glassdoor
StockTake: AdAlta | The Australian
Adalta White 2018, Order online Spanish wines of D.O Terra Alta
#1ad #webinar | AdAlta Ltd
ASX:1AD - AdAlta presenting at 3rd ANZ Biologics Festival
AdAlta gets A$2M investment from SYNthesis BioVentures | AdAlta Ltd ...
#1ad #biologics | AdAlta Ltd
#adalta #ad214 #1ad #fibrosis | AdAlta Ltd
AdAlta secures A$1.28 million in rights offer to advance AD-214 - YouTube
ADALTA DEVELOPMENT LTD on LinkedIn: This is a powerful and intensive ...
Adalta Global Inc. | LinkedIn
AdAlta (ASX:1AD) CEO & Managing Director Dr Tim Oldham joins IPF ...
AdAlta Consultancy – Expert marketing and strategic support for the ...
AdAlta (ASX:1AD) CEO, Tim Oldham, presented at the ChinaBio Partnering ...
AdAlta participates in US Emerging Growth Conference 13 July, 2023 ...
AdAlta (ASX:1AD): Connecting 'Eastern' cellular immunotherapies with ...
AdAlta says new AD-214 dosing models enhance partnering potential - YouTube
AdAlta (ASX:1AD) - SYNthesis BioVentures partnership webinar recording ...
Adalta tinto 2019 - Adalta
Inicio - Adalta
AdAlta Ltd on LinkedIn: "AdAlta is also delving into the popular ...
AdAlta announces it will prioritise 'East to West' cellular ...
ADALTA DEVELOPMENT LTD on LinkedIn: This course offers the practical ...
Adalta Capital Management - Crunchbase Company Profile & Funding
ADALTA DEVELOPMENT LTD on LinkedIn: Looking for a management and ...
AdAlta (ASX:1AD) is presenting at the 3rd ANZ Biologics Festival being ...
Navigate change confidently with the "Managing Change" course by Adalta ...
AdAlta Ltd on LinkedIn: #asx #biotech #fibrosis #ipf #adalta
Adalta Tinto - Lafuente - La tienda online de vinos y destilados más ...
AdAlta presents at Twilight Investor Briefing - AdAlta - next ...
AdAlta Ltd on LinkedIn: AdAlta Limited (ASX:1AD) will present at an ...
| Bioshares
ADALTA, expert-comptable à Perpignan et en Cerdagne
"AdAlta has ranked its East to West cellular immunotherapy strategy as ...
Unlocking Chronic Diseases with Next-Gen i-body Platform Technology ...
Long Shortz with AdAlta: Growing in confidence every day for fibrotic ...
AdAlta: A big development for fibrosis sufferers … and it could be ...
AdAlta’s Ad-214 extension study reaches milestone for Phase II clinical ...
Pulmonary fibrosis awareness month, which extends across September 2024 ...
Road to 2025: AdAlta's push to advance lead drug AD-214 for deadly IPF ...
AdAlta, SYNthesis collaborate on cell-based cancer immunotherapy | NT News
OriginLab Distributor - Italy, Greece, and Malta
Catalogo Generale catalogo completo su: www.adalta.it
Training Provider of the Year Winners - CMI
#adalta #ad214 #fibroticdiseases #biotechnology #cellularimmunotherapy ...
AdAlta's latest results bolster safety profile and dose selection for ...
CTPL to be AdAlta's preferred manufacturer of immunotherapies - Cell ...
AdAlta, Industry and Community, La Trobe Industry, Case studies, La ...
Channel Partner Listing | Bentley Systems
